CSCamila Parcianello Saccol

Camila Parcianello Saccol

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Camila Parcianello Saccol has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Orodispersible Tablets: from Concept to Data Analysis of Valid Records in Brazil

    by Natália Flores Jacobi, Camila Parcianello Saccol, Letícia Cruz

    Orodispersible tablets (ODT) are fast-disintegrating dosage forms for oral administration that do not require swallowing or the intake of water. Despite their convenience, ODT are rarely prescribed in Brazil. This study surveys data on valid ODT in the country, focusing on pharmacological classes and target populations. Additionally, it examines the composition and use instructions in package inserts to clarify their peculiarities. Registrations were obtained from online research on the Brazilian Health Regulatory Agency (ANVISA) website, with further information provided in the package insert available on the Bulário Eletrônico of ANVISA. A total of 50 valid ODT registrations were found in Brazil. The antiemetic and antidepressant classes, represented by ondansetron hydrochloride and mirtazapine, are the main drugs available as ODT. Descriptive and illustrative instructions on correct drug administration on the tongue were found. In excipient analysis, microcrystalline cellulose, croscarmellose, crospovidone, or sodium starch glycolate were frequently used as superdisintegrants. Mannitol is also present as a diluent and sweetener, which helps mask the unpleasant flavor of the ODT. In general, ODT registered in Brazil combine a simple composition with practical use, making them an excellent option for patients with special needs and with potential for growth in the Brazilian pharmaceutical market.

  • Open Access

    Karaya/Gellan-Gum-Based Bilayer Films Containing 3,3′-Diindolylmethane-Loaded Nanocapsules: A Promising Alternative to Melanoma Topical Treatment

    by Jéssica Brandão Reolon, Camila Parcianello Saccol, Bárbara Felin Osmari, Daiane Britto de Oliveira, Vinicius Costa Prado, Fernanda Licker Cabral, Lucas Saldanha da Rosa, Giancarlo Cervo Rechia, Daniela Bitencourt Rosa Leal, Letícia Cruz

    This study aimed to incorporate nanocapsules containing 3,3′-diindolylmethane (DIM) with antitumor activity into a bilayer film of karaya and gellan gums for use in topical melanoma therapy. Nanocarriers and films were prepared by interfacial deposition of the preformed polymer and solvent casting methods, respectively. Incorporating DIM into nanocapsules increased its antitumor potential against human melanoma cells (A-375) (IC50 > 24.00 µg/mL free DIM × 2.89 µg/mL nanocapsules). The films were transparent, hydrophilic (θ < 90°), had homogeneous thickness and weight, and had a DIM content of 106 µg/cm2. Radical ABTS+ scavenger assay showed that the DIM films presented promising antioxidant action. Remarkably, the films showed selective bioadhesive potential on the karaya gum side. Considering the mechanical analyses, the nanotechnology-based films presented appropriate behavior for cutaneous application and controlled DIM release profile, which could increase the residence time on the application site. Furthermore, the nanofilms were found to increase the permeation of DIM into the epidermis, where melanoma develops. Lastly, the films were non-hemolytic (hemolysis test) and non-irritant (HET-CAM assay). In summary, the combination of karaya and gellan gum in bilayer films that contain nanoencapsulated DIM has demonstrated potential in the topical treatment of melanoma and could serve as a viable option for administering DIM for cutaneous melanoma therapy.